Towards Healthcare
Japan Cell Cancer Vaccine Market Captures USD 576.4 Million by 2034

Japan Cell Cancer Vaccine Market Strategic Recommendations with Performance

According to forecasts, the global Japan cell cancer vaccine market will grow from USD 320.6 million in 2024 to USD 576.4 million by 2034, with an expected CAGR of 6.04%. The Japan cell cancer vaccine market is expanding due to rising incidences of cancer as well as increasing use of peptide-based cancer vaccines.

Category: Therapeutic Area Insight Code: 5789 Format: PDF / PPT / Excel

Japan Cell Cancer Vaccine Market Size, Dynamics and Key Players

The Japan cell cancer vaccine market size is calculated at US$ 320.6 in 2024, grew to US$ 340 million in 2025, and is projected to reach around US$ 576.4 million by 2034. The market is expanding at a CAGR of 6.04% between 2025 and 2034.

There is a rise in the demand for the use of cell cancer vaccines in the treatment of different types of cancer in Japan. At the same time, new developments are also being conducted along with the use of AI. This, in turn, is leading to new collaborations as well as launches. Furthermore, the growing use of therapeutic and vector-based vaccines is also driving their use. Additionally, their target action and reduced toxicity are increasing their acceptance rates, improving patient outcomes. Thus, all these growing developments are promoting the Japan cell cancer vaccine market growth.

Japan Cell Cancer Vaccine Market Size 2024 - 2034

Key Takeaways

  • Japan cell cancer vaccine sector is pushing the market to USD 320.6 million in 2024.
  • Long-term projections show USD 576.4 million valuation by 2034.
  • Growth is expected at a steady CAGR of 6.04% in between 2025 to 2034.
  • By vaccine type, the therapeutic cancer vaccines segment dominated the market share in 2024.
  • By vaccine type, the preventive cancer vaccines segment is expected to be the fastest growing at a notable CAGR during the forecast period.
  • By indication type, the prostate cancer segment dominated the market in 2024.
  • By indication type, the cervical cancer segment is expected to be the fastest growing during the forecast period.
  • By technology type, the vector-based vaccines segment dominated the global Japan cell cancer vaccine market in 2024.
  • By technology type, the DNA/RNA-based vaccines segment is expected to be the fastest growing during the forecast period.

Market Overview

To stimulate an adaptive immune response as well as to imitate the natural immune process to fight against tumor antigens, the use of autologous antigen-presenting cells, autologous patient-derived tumor cells, and allogeneic cancer cell lines is used by the cell-based cancer vaccines. These cell cancer vaccines are being preferred in the treatment of a variety of cancer types due to their significant clinical benefits. At the same time, new vaccine therapies are also being discovered. Thus, the growing use of these vaccines will continue to evolve, providing potential applications in the field of anti-cancer therapy.

  • In May 2025, a collaboration between the V Foundation for Cancer Research and Cancer Vaccine Coalition (CVC) was announced for the development of cancer vaccines. Moreover, the clinical trials conducted for the therapeutic breast cancer vaccines, which are the new interest for the development of targeted treatment approaches, will be funded by this collaboration. (Source - Cision
  • In May 2025, seven grant winners were announced by the American Urological Association (AUA), as a part of a partnership initiative with Pfizer External Research & Grants (ER&G) that focused on the enhancement of the quality of care for advanced prostate cancer patients, where $1.5 million was equally spilt between them. This funding was granted for seven innovative projects on behalf of the Pfizer-Astellas Alliance. (Source - Morningstar)

Why is the Use of AI Increasing in the Japan Cell Cancer Vaccine Market?

To improve the design and development of cancer vaccines, the use of AI is increasing. At the same time, by anticipating the patient responses, the AI helps in enhancing the optimization of personalized vaccine strategies, epitope design, and mRNA and DNA vaccine instructions. Moreover, the efficacy and precision of the cancer vaccines are also improved as they help to discover new therapeutic targets and interpretations of complex biological datasets. Additionally, its use in the development of personalized cancer vaccines and immunotherapies is also increasing, enhancing cancer vaccine development.

Market Dynamics

Driver

Rising Incidence of Cancer

The rising incidence of cancer in Japan is increasing the demand for the use of cancer cell vaccines. As the use of traditional treatments is often associated with side effects, the use of these vaccines is growing. Thus, the use of these vaccines stimulates the immune system of the body, showing reduced toxic effects of the treatment. At the same time, the use of personalized treatment approaches is also enhancing their use. Therefore, the use of cell cancer vaccines is providing targeted action, enhancing the patient outcome. Thus, this promotes the Japan cell cancer vaccine market growth.

Japan Cancer Cases in 2024

The graph represents the total number of cancer cases reported in Japan in year of 2024. It indicates that there will be a rise in cases of cancer. Hence, it increases the demand for cell cancer vaccines for their effective management. Thus, this in turn will ultimately promote the market growth.

Restraint

High Price

The cell cancer vaccines are costly, which in turn, limits their adoption by patients. At the same time, the lack of infrastructure also makes their production expensive, adding to the cost. As well as the regulatory procedures also contribute to their enhanced cost. Additionally, the delay in the reimbursement also reduces their use. Thus, the high prices of the cancer vaccines may restrain the market growth.

Opportunity

Why is the Growing Use of Peptide-Based Cancer Vaccines an Opportunity in the Japan Cell Cancer Vaccine Market?

The growing cancer cases is increasing the demand for cancer vaccines. At the same time, rising developments in the peptide-based cancer vaccines are also attracting patient, promoting their use. These vaccines stimulate the T-cells, enhancing the immune responses. Moreover, its use in the early stages of cancer is increasing due to its affordability. Thus, their use in the treatment of different types of cancer is increasing. Additionally, new developments to enhance the action, as well as to develop new combination approaches, are also increasing. Thus, its growing use is promoting the Japan cell cancer vaccine market growth.

For instance,

  • In January 2025, a novel delivery system was developed by the Terasaki Institute for Biomedical Innovation, which can enhance the effectiveness of the peptide-based cancer vaccines. Thus, the use of lipopeptide hydrogels (LPHs), which consist of adjuvant-like properties, helped in enhancing the immune responses. (Source - News medical life science)

Segmental Insights

Which Vaccine Type Segment Held the Dominating Share of the Japan Cell Cancer Vaccine Market in 2024? 

By vaccine type, the therapeutic cancer vaccines segment held the dominating share in the market in 2024. The use of therapeutic cancer vaccines increased due to the increased cancer cases. At the same time, the development of personalized therapeutic cancer vaccines also contributed to the same. Moreover, it was also used in combination with other therapies, enhancing the market growth.

By vaccine type, the preventive cancer vaccines segment is expected to show the fastest growth rate at a notable CAGR during the predicted time. The growing awareness of cancer is increasing the use of preventive cancer vaccines. Moreover, various vaccination campaigns are also increasing their use. Additionally, their use is also promoted by the government.

How Prostate Cancer Segment Dominated the Japan Cell Cancer Vaccine Market in 2024?

By indication type, the prostate cancer segment led the market in 2024. Due to the growing incidence of prostate cancer in the aging population in Japan, the use of prostate cancer vaccines increased. With the use of these vaccines, the immune response was enhanced, providing successful results. Thus, this in turn enhanced their use, contributing to the market growth.

By indication type, the cervical cancer segment is expected to show the highest growth during the forthcoming period. The growing awareness, as well as the vaccination campaigns for cervical cancer, is increasing the use of cell cancer vaccines. Moreover, to eliminate cervical cancer, the use of cost-effective cancer vaccines is also increasing.

What Made Vector-Based Vaccines the Dominant Segment in the Japan Cell Cancer Vaccine Market in 2024?

By technology type, the vector-based vaccines segment held the largest share in the global market in 2024. The vector-based vaccines stimulated the T cell responses, enhancing the action, due to which their use in Japan increased. At the same time, the development of personalized vector-based vaccines increased their acceptance rate. Thus, this promoted the market growth.

By technology type, the DNA/RNA-based vaccines segment is expected to show the fastest growth rate during the upcoming years. Due to the target-specific action, the use of DNA/RNA-based vaccines is increasing. This, in turn, also enhances their development for personalized cancer vaccines. Furthermore, the growing investments from the government and private sectors are also enhancing their production and acceptance rates.

Regional Insights

Japan Driven by Increasing Cancer Cases

The Japan cell cancer vaccine market is expected to grow significantly during the forecast period. The growing incidence of cancer cases in Japan is increasing the demand for cancer cell vaccines. At the same time, due to these rising cancer cases, the interest in the development of new cell-based cancer vaccines is also increasing. This, in turn, increases the development of personalized cancer vaccines. As these vaccines show reduced toxicity and side effects, their acceptance rate also increases. Additionally, the presence of advanced technologies is also driving their production as well as innovations. Moreover, the growing development is also supported by the government as well as the private sector. Thus, all these factors promote the market growth.

Which are the Top Companies in the Japan Cell Cancer Vaccine Market?

Japan Cell Cancer Vaccine Market Companies

Latest Announcements by Industry Leaders

  • In May 2025, Kristen Dahlgren, the CVC founder and former NBC correspondent, stated that, with the rising medical breakthroughs, new options are being discovered to enhance the immune system to fight against cancer, which in turn will provide better treatment options, avoiding the need to wait for decades. Moreover, with their collaboration with the V Foundation, the breast cancer vaccine research and the trials will be enhanced by the funding provided by them. (Source - Morningstar)
  • In February 2025, Dr. Balachandran stated that the use of personalized mRNA vaccines in the treatment of pancreatic cancer patients is providing promising results as it targets neoantigens present in every patient’s tumor, promoting their use. Furthermore, he stated that if this approach is providing successful results for pancreatic cancer, then theoretically, the development of therapeutic vaccines for the treatment of other cancer types may also be possible. (Source - Memorial Sloan Kettering Cancer Center)

Recent Developments in the Japan Cell Cancer Vaccine Market

  • In April 2025, the personalized cancer vaccine, that is EVX-01, was announced to show promising results as per Evaxion Biotech A/S. It was stated that a tumor-specific immune response was initiated by 80% of the vaccine's targets, surpassing other vaccine candidates. (Source- Nasdaq)
  • In January 2025, a customised cancer vaccine can be developed within just 48 hours for an individual with the use of Artificial Intelligence (AI), which was highlighted by Oracle chairman Larry Ellison. Moreover, he also highlighted that with the use of AI and robotic systems, the development of personalised mRNA vaccines against cancer is possible. (Source - India Today)

Segments Covered in the Report

By Vaccine Type

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines
  • Oncolytic Viruses

By Indication

  • Prostate Cancer
  • Cervical Cancer

By Technology

  • Peptide-based Vaccines
  • Vector-based Vaccines
  • DNA/RNA-based Vaccines
  • Last Updated: 30 June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations.

Learn more about Kesiya Chacko

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

The Japan cell cancer vaccine market is projected to reach USD 576.4 million by 2034, growing at a CAGR of 6.04% from 2024 to 2034.

The growth in the Japan cell cancer vaccine market is due to the increasing incidence of cancer cases.

The Japan cell cancer vaccine market includes 3 segments such as by vaccine type, by indication, and by technology.

Some key players include Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Company Limited.

Key trends include the rising development of cancer vaccines, as well as growing collaborations.

Stimulating an adaptive immune response and imitating the natural immune process to fight against cancer is the mechanism of action of cell-based cancer vaccines.

The therapeutic cancer vaccines were the most commonly used cancer vaccines in Japan.

Ganjoho, WHO, National Institutes of Health.